HEDERAGENIN

Possibly Marketed Outside US

First approved in 2018

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C30H48O4
Molecular Weight	472.6997
Optical Activity	UNSPECIFIED
Defined Stereocenters	9 / 9
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O

InChI

InChIKey=PGOYMURMZNDHNS-MYPRUECHSA-N

InChI=1S/C30H48O4/c1-25(2)13-15-30(24(33)34)16-14-28(5)19(20(30)17-25)7-8-22-26(3)11-10-23(32)27(4,18-31)21(26)9-12-29(22,28)6/h7,20-23,31-32H,8-18H2,1-6H3,(H,33,34)/t20-,21+,22+,23-,26-,27-,28+,29+,30-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C30H48O4
Molecular Weight	472.6997
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	9 / 9
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26557859 | https://www.ncbi.nlm.nih.gov/pubmed/26481049

Hederagenin is a triterpenoid saponin. It can inhibit LPS-stimulated expression of iNOS, COX-2, and NF-κB. Hederagenin exhibits multiple pharmacological activities in the treatment of hyperlipidemia, antilipid peroxidation, antiplatelet aggregation, liver protection, antidepression, anti-inflammation.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Apoptosis 156 Target ID: map04210 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25342273	Activator 1447		1.39 µM [IC50]
Pancreatic elastase 3 Target ID: CHEMBL2096984 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8554461	Inhibitor 8504		40.6 µM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Atherosclerosis 76 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26557859	Primary	Preclinical	Unknown Approved Use Unknown
Colon cancer 66 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25342273 https://www.ncbi.nlm.nih.gov/pubmed/23992864	Primary	Basic research	Unknown Approved Use Unknown
Venous insufficiency 2 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8554461	Primary	Basic research	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Hederagenin, a major component of Clematis mandshurica Ruprecht root, attenuates inflammatory responses in RAW 264.7 cells and in mice.	2015-12	26481049
Experimental Study of Antiatherosclerosis Effects with Hederagenin in Rats.	2015	26557859

Patents

Sample Use Guides

In Vivo Use Guide

Hederagenin, dissolved in 40% polyethylene glycol, was administered orally to mice at doses of 5 or 30 mg/kg/day for four consecutive days.

Route of Administration: Oral

In Vitro Use Guide

Treatment with hederagenin (10, 30 and 100uM) resulted in inhibited levels of protein expression of lipopolysaccharide-stimulated iNOS, COX-2, and NF-κB as well as production of NO, PGE2, TNF-α, IL-1β, and IL-6 induced by lipopolysaccharide in RAW 264.7 cells.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 19:54:47 GMT 2025` Edited by `admin` on `Mon Mar 31 19:54:47 GMT 2025`
Record UNII	RQF57J8212
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

HEDERAGENIN

Common Name

English

NSC-24954

Preferred Name

English

ASTRANTIAGENIN E

Common Name

English

OLEAN-12-EN-28-OIC ACID, 3,23-DIHYDROXY-, (3.BETA.,4.ALPHA.)-

Common Name

English

OLEAN-12-EN-28-OIC ACID, 3.BETA.,23-DIHYDROXY-

Common Name

English

CAULOSAPOGENIN

Common Name

English

HEDERAGENIC ACID

Common Name

English

HEDERAGENIN [MI]

Common Name

English

HEDERAGENIN, (+)-

Common Name

English

HEDERAGENOL

Common Name

English

HEDERAGENINE

Common Name

English

Code System Code Type Description

FDA UNII

RQF57J8212